Iterum Therapeutics PLC (NASDAQ: ITRM) is a clinical-stage biopharmaceutical company focused on developing antibiotics to treat drug-resistant bacterial infections. The company has no product revenue as of the 10-K filed February 7, 2025; it has operated exclusively on capital raises, burning $26.8 million in cash from operations in FY2024. Its lead asset, ORLYNVAH, received FDA approval and was confirmed in October 2024 to carry ten years of total marketing exclusivity under the GAIN Act, including the five-year QIDP extension. A second candidate, sulopenem, remains in development. Iterum is incorporated in Ireland and audited by KPMG Dublin. Commercialization of ORLYNVAH in the United States, targeting uncomplicated urinary tract infections caused by quinolone-resistant pathogens including E. coli, is contingent on the outcome of a stated strategic process and the company's ability to raise additional capital.

Revenue model

No product revenue as of the filing date. The company is pre-commercial and funds operations through capital raises, including a Pfizer Promissory Note on which interest accrued in FY2024. Future revenue, if any, is expected to come from product sales of ORLYNVAH, potentially through a commercial partner.

Products and services

ORLYNVAH: FDA-approved oral antibiotic with ten years of U.S. marketing exclusivity confirmed October 2024 (QIDP designation under the GAIN Act), targeting uncomplicated urinary tract infections (uUTI). Sulopenem: additional antibiotic candidate in development, not yet approved as of the filing date.

Customers and end markets

Target end market is community-setting physicians treating uncomplicated urinary tract infections, with a focus on infections caused by E. coli resistant to quinolone antibiotics. No commercial customers as of the filing date.

Value-chain role

Drug developer and prospective commercializer. Manufacturing is outsourced; the company incurs costs for clinical and commercial material production, manufacturing validation batches, and reservation fees. Sales, marketing, and distribution infrastructure had not been built as of the filing date, with commercialization contingent on strategic process outcome and capital availability.

Geographic exposure

Primary regulatory and commercial focus is the United States. The company is incorporated in Ireland and subject to EU GDPR and EU pricing and reimbursement frameworks, indicating some European operational and regulatory presence. Auditor is based in Dublin, Ireland.

Source: SEC 10-K, filed 2025-02-07

Industry: Pharmaceutical Preparations Peers: AVADEL PHARMACEUTICALS PLC Endo International plc GH Research PLC Jazz Pharmaceuticals PLC Keenova Therapeutics plc Nabriva Therapeutics plc